Lev Gerlovin is a speaker during the session titled “Assess Value When Innovating to Establish Greater Benefits Relative to Costs.”
For more information on this event, click here.
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Lev Gerlovin is a speaker during the session titled “Assess Value When Innovating to Establish Greater Benefits Relative to Costs.”
For more information on this event, click here.
In spring 2023, CRA’s Life Sciences Practice held a roundtable discussion with Medical Affairs leaders to better understand obstacles prohibiting their teams...
In December 2021, the Regulation on Health Technology Assessment (HTA), as originally proposed by the European Commission, was adopted.[1] The Regulation...